Maxcyte Inc's (LON:MXCT) Doug Doerfler talks to Proactive London about their full-year revenues which are on track to be 'slightly above' current market expectations.
Doerfler discusses what he describes as an 'extraordinary first half' with half year revenue 30% higher than the same period in 2019, which were 30% over 2018. There are now 11 commercial deals in total, which is a huge increase from four this time last year, with 90 clinical products under license, which is twice what MaxCyte had last year.
He goes on to explain the 'exciting increase' in their commercial activity, with revenue driven by high-margin recurring annual fees from its cell therapeutics business, instrument sales and clinical milestone payments.
